Clinical Chemistry Analyzers Market

Global Clinical Chemistry Analyzers Market Size (2024 to 2032)

The size of the global clinical chemistry analyzers market was worth USD 13.86 billion in 2023. The global market is anticipated to grow at a CAGR of 6.44% from 2024 to 2032 and be worth USD 24.31 billion by 2032 from USD 14.75 billion in 2024. 

MARKET DRIVERS

Technological advancements play an essential role in transforming the clinical chemistry analyzer market.

Automation in the Clinical chemistry analyzers has improved the testing volumes and efficiency and minimized human errors. Erba XL 640 is a fully automated random-access clinical chemistry analyzer with an autoloader. This equipment helps in establishing better workflow and helps in achieving faster TAT. Furthermore, strengthening favorable reimbursement policies and technologies to develop flexible instruments is possible for the key players by adopting automated chemistry analyzers.

The evolution of technology, rising R&D activities, and integration of advanced software technologies are expected to shape the market in the future.

Next-generation clinical chemistry analyzers will improve hospital workflow, point-of-care diagnostics centers, and laboratories. Technical innovations such as next-generation microfluidic devices can efficiently separate CTCs from whole blood. Implementing favorable government initiatives, schemes, and funding to develop diagnostics is expected to have various opportunities for the market.

Y-O-Y growth in the aging population significantly boosts the clinical chemistry analyzers market.

Due to age-related diseases such as diabetes, hypertension, cardiovascular, liver, and other diseases in senior people, the market is expected to increase significantly. According to United Nations, 703 million people aged 64 and above in 2019. As per the United States Census Bureau’s Statistics, the number of elderly populations is expected to increase by 19 million between 2020-2030. Furthermore, the number of people aged above 85 will likely triple from an estimated 6 million to about 24 million by 2060. Such a rise in the geriatric population will boost the market forward.

MARKET RESTRAINTS

The high cost of analyzers is a significant restraint to the growth of the clinical chemistry analyzers market. Laboratories cannot afford high-cost instruments. In addition, the shortage of skilled technicians and the gap between the supply and demand of pathologists and technicians are significant challenges to market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Clinical Chemistry Analyzers Market Analysis By Test Type

• Basic Metabolic Panels
• Electrolyte Panels
• Liver Panels
• Lipid Profiles
• Renal Panels
• Thyroid Function Panels
• Specialty Chemical Tests

The basic metabolic panel had the largest share of the clinical chemistry analyzers market in 2023. It gains significant demand for newborn screening, which allows early detection of congenital genetic and metabolic disorders. Rising importance, awareness of point-of-care testing, and the growing prevalence of lifestyle-induced diseases are the key drivers of the market. Basic metabolic panels provide clinical information regarding the issues caused by a chemical imbalance.

Global Clinical Chemistry Analyzers Market Analysis By Product Type

• Analyzers
• Reagents

Based on the product type, the reagents segment led the market in 2023, owing to the vast array of reagents present in the market. Reagents must be the highest-efficiencies, have optimum sensitivity, and ensure minimized performance variation.

Global Clinical Chemistry Analyzers Market Analysis By End-User

• Hospitals and Clinics
• Diagnostic Laboratories
• Research Laboratories & Institutes

Based on the end-user, the hospital segment accounted for the most significant share of the market in 2023, owing to the frequent readmission and large sample volumes. Additionally, favorable infrastructure facilitates and increasing government initiatives are favoring this segment to register better share among other end-user types.

REGIONAL ANALYSIS

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Geographically, North America dominated the market for clinical chemistry analyzers worldwide in 2023. This region's demand for clinical chemistry analyzers is expected to remain high due to the need for routine diagnostic procedures. In addition, the rising prevalence of cancer and diabetes, an aging population, and increasing awareness are majorly putting this region first, accounting for a leading share of the global market among other regions. Furthermore, one of the major market players, Siemens Healthineers, announced the global commercial availability of its Atellica Solution automation-ready immunoassay and chemistry analyzers. DynLife healthcare facility in Canada was the first to adopt this solution. Thus, North America is expected to hold the largest share of the global clinical chemistry analyzers market during the forecast period.

The Asia Pacific is predicted to register the fastest CAGR during the forecast period. Among all, China had the highest share of the APAC market in 2023. A China-based player, Snibe, has launched the new Bioassays C8 automatic biochemistry analyzer. It is used for powerful performance and scalability. Rapid urbanization, the launch of innovative products in the region, and the adoption of a sedentary lifestyle are the factors driving the region forward.

Europe's steady growth accounted for a substantial share of the global clinical chemistry analyzers market in 2023. Small and medium laboratories are expected to drive the European market.

Due to improving healthcare infrastructure and expanding distribution network clinical chemistry analyzer market in Latin America is expected to grow during the forecast period.

TOP COMPANIES IN THIS MARKET

Companies playing a significant role in the global clinical chemistry analyzers market profiled in this report are Abbott Laboratories, Beckman Coulter Inc., Biobase Biodusty (Shandong), Co., Ltd., Dirui Industrial Co., Ltd., EKF Diagnostics, ELITechGroup, Erba Mannheim, F. Hoffmann-La Roche Ltd., Genrui Biotech Inc., Hitachi High-Tech Corporation, Horiba, Ltd, Thermo Fisher Scientific and KPM Analytics, Inc.

RECENT HAPPENINGS IN THIS MARKET

• In January 2020, Sysmex invested in Astrego Diagnostics to develop new urinalysis solutions for the primary care business.
• In April 2019, NexTech AR Solutions announced an agreement with Block Scientific, a primary provider of clinical laboratory equipment, to supply 3D product models through its AR eCommerce platform.